CoChat

Targeting HIF-1 alpha transcriptional activity drives cytotoxic immune effector cells into melanoma and improves combination immunotherapy

Open access
Lequeux, Audrey, Noman, Muhammad Zaeem, Xiao, Malina, Van Moer, Kris, Hasmim, Meriem, Benoit, Alice, Bosseler, Manon, Viry, Elodie, Arakelian, Tsolere, Berchem, Guy, Chouaib, Salem, Janji, Bassam · 2021 · Oncogene

The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.

Abstract

Hypoxia is a key factor responsible for the failure of therapeutic response in most solid tumors and promotes the acquisition of tumor resistance to various antitumor immune effectors. Reshaping the hypoxic immune suppressive tumor microenvironment to improve cancer immunotherapy is still a relevant challenge. We investigated the impact of inhibiting HIF-1α transcriptional activity on cytotoxic immune cell infiltration into B16-F10 melanoma. We showed that tumors expressing a deleted form of HIF-1α displayed increased levels of NK and CD8+effector T cells in the tumor microenvironment, which was associated with high levels of CCL2 and CCL5 chemokines. We showed that combining acriflavine, reported as a pharmacological agent preventing HIF-1α/HIF-1β dimerization, dramatically improved the benefit of cancer immunotherapy based on TRP-2 peptide vaccination and anti-PD-1 blocking antibody. In melanoma patients, we revealed that tumors exhibiting high CCL5 are less hypoxic, and displayed high NK, CD3+, CD4+and CD8+T cell markers than those having low CCL5. In addition, melanoma patients with high CCL5 in their tumors survive better than those having low CCL5. This study provides the pre-clinical proof of concept for a novel triple combination strategy including blocking HIF-1α transcription activity along vaccination and PD-1 blocking immunotherapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41388-021-01846-x

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Deletion of the heterodimerization domain of HIF-1α inhibits its transcriptional activity in vitro. A Crystal structure of the heterodimeric HIF-1α: ARNT Complex with Hypoxia-response element (HRE) DNA generated from Protein Data Bank Japan (PDBj) (https://pdbj.org/mine_molmil?pdbid = 4zpr). The HIF-1α domain responsible for the dimerization with HIF-1β is outlined. B HIF-1α (FL) and HIF-1α (Del) domain structure: The deleted sequence in HIF-1α (Del) goes from amino acid 65 to amino acid 179 within the HIF-1β dimerization domain. HLH, basic helix-loop-helix domain; PAS, PER-ARNT-SIM domains A and B; ODD, oxygen-dependent domain; N- and C-TAD, N- and C-transactivation domains; NLS, nuclear localization signal sequence. C RT-PCR detection of HIF-1α (FL) and HIF-1α (Del) showing fragments of 576 and 235 bp for HIF-1α FL and HIF-1α, respectively. The panel inside indicates the design strategy of primers. F: Forward primer and R: Reverse primer. D Luciferase report assay performed on B16-F10 cells expressing HIF-1α (FL) and HIF-1α (Del) and cultured under normoxia (N) or hypoxia (H). Results are reported as relative Luciferase activity and normalized to the activity detected in control normoxic B16-F10 cells expressing HIF-1α (FL) as shown in the figure. Data represent the mean of four independent experiments with SEM. Statistically significant difference (indicated by asterisks) are shown (**p < 0.005). E Proximity Ligation Assay was performed in B16-F10 cells expressing HIF-1α (FL) or HIF-1α (Del) cultured under hypoxia (0.1% pO2, H) for 24 h. The appearance of red dots is indicative of the complex formed between HIF-1α/HIF-1β. Lower images represent a magnification of the delineated area of the upper images. Scale bar: 50 µm. Images are representative of eight acquisitions from HIF-1α (FL) or HIF-1α (Del) expressing cells. Lower graph represents the quantification of red dots present in the nucleus of all cells in the upper images. Results are shown as mean ± SEM (error bars). **** = p < 0.0001 determined by two-tailed unpaired Student’s t test. F RT-qPCR quantification of Ca-9, Slc2a1, and Vegf gene expression in HIF-1α FL (FL) and HIF-1α Del (Del) B16-F10 cells cultured under normoxia (21% pO2, N) or hypoxia (0.1% pO2, H) conditions for 24 h. Results are reported as fold change (FC) and represent the average of three independent experiments. Error bars indicate mean ± SEM. ** = p < 0.01, *** = p < 0.001 determined by unpaired two-tailed Student’s t test. G ELISA quantification of VEGF protein levels in the supernatant of cells described in E. Data are reported in pg/ml and represent three independent experiments. Results are shown as mean ± SEM (error bars). * = p < 0.05 determined by one-tailed Student’s t test. H Western-blot analysis of HIF-1α, LDHA, and Glut−1 protein expression in HIF-1α (FL) and HIF-1α (Del) B16-F10 cells cultured under normoxia (21% pO2, N) or hypoxia (0.1% pO2, H) conditions for 24 h. Actin was used as a loading control. I Confocal microscopy analysis of subcellular localization of HIF-1α (green) in B16-F10 cells expressing either HIF-1α (FL) or HIF-1α (Del) cultured under normoxia (21% pO2, N) or hypoxia (0.1% pO2, H) conditions for 24 h at the same cell density. Nuclei are stained with DAPI (blue). Individual and merged images of HIF-1α and DAPI staining are shown. Scale bar: 50 μm.
Fig. 1 Deletion of the heterodimerization domain of HIF-1α inhibits its transcriptional activity in vitro. A Crystal structure of the heterodimeric HIF-1α: ARNT Complex with Hypoxia-response element (HRE) DNA generated from Protein Data Bank Japan (PDBj) (https://pdbj.org/mine_molmil?pdbid = 4zpr). The HIF-1α domain responsible for the dimerization with HIF-1β is outlined. B HIF-1α (FL) and HIF-1α (Del) domain structure: The deleted sequence in HIF-1α (Del) goes from amino acid 65 to amino acid 179 within the HIF-1β dimerization domain. HLH, basic helix-loop-helix domain; PAS, PER-ARNT-SIM domains A and B; ODD, oxygen-dependent domain; N- and C-TAD, N- and C-transactivation domains; NLS, nuclear localization signal sequence. C RT-PCR detection of HIF-1α (FL) and HIF-1α (Del) showing fragments of 576 and 235 bp for HIF-1α FL and HIF-1α, respectively. The panel inside indicates the design strategy of primers. F: Forward primer and R: Reverse primer. D Luciferase report assay performed on B16-F10 cells expressing HIF-1α (FL) and HIF-1α (Del) and cultured under normoxia (N) or hypoxia (H). Results are reported as relative Luciferase activity and normalized to the activity detected in control normoxic B16-F10 cells expressing HIF-1α (FL) as shown in the figure. Data represent the mean of four independent experiments with SEM. Statistically significant difference (indicated by asterisks) are shown (**p < 0.005). E Proximity Ligation Assay was performed in B16-F10 cells expressing HIF-1α (FL) or HIF-1α (Del) cultured under hypoxia (0.1% pO2, H) for 24 h. The appearance of red dots is indicative of the complex formed between HIF-1α/HIF-1β. Lower images represent a magnification of the delineated area of the upper images. Scale bar: 50 µm. Images are representative of eight acquisitions from HIF-1α (FL) or HIF-1α (Del) expressing cells. Lower graph represents the quantification of red dots present in the nucleus of all cells in the upper images. Results are shown as mean ± SEM (error bars). **** = p < 0.0001 determined by two-tailed unpaired Student’s t test. F RT-qPCR quantification of Ca-9, Slc2a1, and Vegf gene expression in HIF-1α FL (FL) and HIF-1α Del (Del) B16-F10 cells cultured under normoxia (21% pO2, N) or hypoxia (0.1% pO2, H) conditions for 24 h. Results are reported as fold change (FC) and represent the average of three independent experiments. Error bars indicate mean ± SEM. ** = p < 0.01, *** = p < 0.001 determined by unpaired two-tailed Student’s t test. G ELISA quantification of VEGF protein levels in the supernatant of cells described in E. Data are reported in pg/ml and represent three independent experiments. Results are shown as mean ± SEM (error bars). * = p < 0.05 determined by one-tailed Student’s t test. H Western-blot analysis of HIF-1α, LDHA, and Glut−1 protein expression in HIF-1α (FL) and HIF-1α (Del) B16-F10 cells cultured under normoxia (21% pO2, N) or hypoxia (0.1% pO2, H) conditions for 24 h. Actin was used as a loading control. I Confocal microscopy analysis of subcellular localization of HIF-1α (green) in B16-F10 cells expressing either HIF-1α (FL) or HIF-1α (Del) cultured under normoxia (21% pO2, N) or hypoxia (0.1% pO2, H) conditions for 24 h at the same cell density. Nuclei are stained with DAPI (blue). Individual and merged images of HIF-1α and DAPI staining are shown. Scale bar: 50 μm.CC BY · PubMed Central
Fig. 2 Targeting the transcriptional activity of HIF-1α inhibits B16-F10 tumor growth and weight, improves mice survival, and increases NK and CD8+ immune effector cells infiltration. A Tumor growth curves of HIF-1α (FL) and HIF-1α (Del) B16-F10 melanoma cells subcutaneously implanted in syngeneic host C57BL/6 mice. Growth curves are reported as the average of 30 (HIF-1α FL) and 29 (HIF-1α Del) mice per group pooled from three independent experiments conducted with at least 6 mice per group. The curve represents mean ± SEM. *** = p < 0.001 determined by unpaired two-tailed Student’s t test. B Weight in grams (g) of HIF-1α (FL) and HIF-1α (Del) B16-F10 melanoma tumors at day 19. Data are reported as the average of 18 (HIF-1α (FL)) and 17 (HIF-1α (Del)) mice pooled from two independent experiments performed with at least 5 mice per group. Results are presented as mean ± SEM. *** = p < 0.001 determined by unpaired two-tailed Student’s t test. Representative pictures of five HIF-1α (FL) and five HIF-1α (Del) tumors are shown in the right. C Kaplan–Meier survival curves of HIF-1α (FL) and HIF-1α (Del) B16-F10 melanoma. Results are generated from 19 tumor-bearing mice per group. Death, tumor necrosis, or tumor size ≥2000 mm3 define the occurrence of a death event. *** = p < 0.0001 determined by the Log-rank (Mantel-Cox) test. D CA-9 immunohistochemical staining (red) performed on HIF-1α (FL) and HIF-1α (Del) B16-F10 melanoma tumors. Scale bar: 300 μm. E Tumor growth curves of HIF-1α (FL) and HIF-1α (Del) B16-F10 melanoma cells subcutaneously transplanted in immuno-deficient NOD scid gamma mouse (NSG) mice. Results are reported as an average of 10 (HIF-1α (FL)) and 9 (HIF-1α (Del)) mice per group. Error bars represent mean ± SEM. ns = not significant determined by unpaired two-tailed Student’s t test. F Immunohistochemical staining of CD45+ cells (red) performed on HIF-1α (FL) and HIF-1α (Del) B16-F10 melanoma. Lower panels represent a magnification of the delineated tumors area of the upper panels. Scale bars: 100 μm (upper panels); 60 μm (lower panels). G Quantification of CD45+ leukocyte infiltration (gated in live cells) in HIF-1α (FL) and HIF-1α (Del) B16-F10 melanoma tumors. Results are reported as the average of 14 mice per group, pooled from two independent experiments conducted with at least 5 mice per group (each dot represents one tumor). Error bars represent mean ± SEM. *** = p < 0.001 determined by two-tailed Student’s t test. H Quantification of NK cells (NK1.1+), CD4+ T effector cells (CD4+), and CD8+ T cells (CD8+) percentage infiltrating HIF-1α (FL) and HIF-1α (Del) B16-F10 melanoma by flow cytometry (gated in live CD45+ cells). Bars represent the average of 14 mice per group pooled from two independent experiments conducted with at least 5 mice per group (each dot represents one tumor). Error bars represent mean ± SEM. ns = not significant, * = p < 0.05 and *** = p < 0.001 determined unpaired two-tailed Student’s t test. I Quantification of CD69+ activated NK cells (left panel) and CD8+ T cells (right panel) infiltrating the B16-F10 melanoma expressing FL or Del HIF-1α. Data are reported as mean florescence intensity (MFI) and represent the average ± SEM (error bars) of 14 mice per group (each dot represents one tumor). Statistically significant differences (indicated by asterisks) are calculated compared to FL tumors using an unpaired two-tailed Student’s t test (ns = not significant). J ELISA quantification of IFN-γ secreted in the microenvironment of B16-F10 melanoma expressing HIF-1α (FL) and HIF-1α (Del). Data are reported in pg/ml standardized to excised tumor weight (gr) and represent the mean of 6 tumors per group ± SEM (each dot represents one mouse). Statistically significant differences (indicated by asterisks) are calculated compared to FL tumors using an unpaired two-tailed Student’s t test (** = p < 0.005).
Fig. 2 Targeting the transcriptional activity of HIF-1α inhibits B16-F10 tumor growth and weight, improves mice survival, and increases NK and CD8+ immune effector cells infiltration. A Tumor growth curves of HIF-1α (FL) and HIF-1α (Del) B16-F10 melanoma cells subcutaneously implanted in syngeneic host C57BL/6 mice. Growth curves are reported as the average of 30 (HIF-1α FL) and 29 (HIF-1α Del) mice per group pooled from three independent experiments conducted with at least 6 mice per group. The curve represents mean ± SEM. *** = p < 0.001 determined by unpaired two-tailed Student’s t test. B Weight in grams (g) of HIF-1α (FL) and HIF-1α (Del) B16-F10 melanoma tumors at day 19. Data are reported as the average of 18 (HIF-1α (FL)) and 17 (HIF-1α (Del)) mice pooled from two independent experiments performed with at least 5 mice per group. Results are presented as mean ± SEM. *** = p < 0.001 determined by unpaired two-tailed Student’s t test. Representative pictures of five HIF-1α (FL) and five HIF-1α (Del) tumors are shown in the right. C Kaplan–Meier survival curves of HIF-1α (FL) and HIF-1α (Del) B16-F10 melanoma. Results are generated from 19 tumor-bearing mice per group. Death, tumor necrosis, or tumor size ≥2000 mm3 define the occurrence of a death event. *** = p < 0.0001 determined by the Log-rank (Mantel-Cox) test. D CA-9 immunohistochemical staining (red) performed on HIF-1α (FL) and HIF-1α (Del) B16-F10 melanoma tumors. Scale bar: 300 μm. E Tumor growth curves of HIF-1α (FL) and HIF-1α (Del) B16-F10 melanoma cells subcutaneously transplanted in immuno-deficient NOD scid gamma mouse (NSG) mice. Results are reported as an average of 10 (HIF-1α (FL)) and 9 (HIF-1α (Del)) mice per group. Error bars represent mean ± SEM. ns = not significant determined by unpaired two-tailed Student’s t test. F Immunohistochemical staining of CD45+ cells (red) performed on HIF-1α (FL) and HIF-1α (Del) B16-F10 melanoma. Lower panels represent a magnification of the delineated tumors area of the upper panels. Scale bars: 100 μm (upper panels); 60 μm (lower panels). G Quantification of CD45+ leukocyte infiltration (gated in live cells) in HIF-1α (FL) and HIF-1α (Del) B16-F10 melanoma tumors. Results are reported as the average of 14 mice per group, pooled from two independent experiments conducted with at least 5 mice per group (each dot represents one tumor). Error bars represent mean ± SEM. *** = p < 0.001 determined by two-tailed Student’s t test. H Quantification of NK cells (NK1.1+), CD4+ T effector cells (CD4+), and CD8+ T cells (CD8+) percentage infiltrating HIF-1α (FL) and HIF-1α (Del) B16-F10 melanoma by flow cytometry (gated in live CD45+ cells). Bars represent the average of 14 mice per group pooled from two independent experiments conducted with at least 5 mice per group (each dot represents one tumor). Error bars represent mean ± SEM. ns = not significant, * = p < 0.05 and *** = p < 0.001 determined unpaired two-tailed Student’s t test. I Quantification of CD69+ activated NK cells (left panel) and CD8+ T cells (right panel) infiltrating the B16-F10 melanoma expressing FL or Del HIF-1α. Data are reported as mean florescence intensity (MFI) and represent the average ± SEM (error bars) of 14 mice per group (each dot represents one tumor). Statistically significant differences (indicated by asterisks) are calculated compared to FL tumors using an unpaired two-tailed Student’s t test (ns = not significant). J ELISA quantification of IFN-γ secreted in the microenvironment of B16-F10 melanoma expressing HIF-1α (FL) and HIF-1α (Del). Data are reported in pg/ml standardized to excised tumor weight (gr) and represent the mean of 6 tumors per group ± SEM (each dot represents one mouse). Statistically significant differences (indicated by asterisks) are calculated compared to FL tumors using an unpaired two-tailed Student’s t test (** = p < 0.005).CC BY · PubMed Central
Fig. 3 The infiltration of NK and CD8+ T cells into HIF-1α Del tumors is associated with the release of CCL5 from tumor cells. A Tumor growth curves of HIF-1α (FL) and HIF-1α (Del) B16-F10 cells transplanted in C57BL/6 mice untreated (Isotype) or treated with NK-depleting antibody (anti-NK1.1). Mice were injected intraperitoneally with 200 µg of Isotype or anti-NK1.1 three days before the engraftment tumor cells and at days 0, 4, 8, 11, 15, 18 and 22 after the engraftment. Results are reported as average of 10 mice per group for [HIF-1α (FL) + Isotype] and [HIF-1α (Del) + anti-NK] groups, and 8 mice per group for [HIF-1α (Del) + Isotype] group. Error bars represent mean ± SEM. ns = not significant, * = p < 0.05, ** = p < 0.01 and *** = p < 0.001 determined by unpaired two tailed Student’s t test. B Tumor growth curves of HIF-1α (FL) and HIF-1α (Del) B16-F10 cells transplanted in untreated (Isotype) or CD8a-depleted (anti-CD8a) C57BL/6 mice. Mice were injected intraperitoneally with 200 µg of Isotype or anti-CD8a antibody three days before the engraftment tumor cells and at days 0, 4, 8, 11, 15, 18 and 22 after the engraftment. Data are reported as average of 8 mice per group for [HIF-1α (FL) + Isotype] group, 5 mice per group for [HIF-1α (Del)+ Isotype] and 7 mice per group for [HIF-1α (Del)+ anti-CD8]. Error bars represent mean ± SEM. ns = not significant, ** = p < 0.01 and *** = p < 0.001 determined by unpaired one tailed Student’s t test. C Cytokines/chemokines profiling in tumor lysate of HIF-1α (FL) and HIF-1α (Del)B16-F10 tumors using Mouse XL Cytokine Array. Left panel: Cytokines/chemokines up- and down-regulated in HIF-1α (Del) compared to HIF-1α (FL) B16-F10 tumor are highlighted in red and in green, respectively. Right panel: signal ratio of HIF-1α Del/HIF-1α FL (Del/FL). Mouse XL Cytokine Array for cytokines/chemokines profiling was performed once. D ELISA quantification of CCL2 and CCL5 in tumor plasma of HIF-1α (FL)and HIF-1α (Del)B16-F10 tumors. Data are reported in pg/ml/g of tumor. Bars represent an average of 8 mice. Error bars represent mean ± SEM. ** = p < 0.01 determined by unpaired two tailed Student’s t test. E ELISA quantification of CCL2 and CCL5 released in the supernatant of HIF-1α (FL) and HIF-1α (Del) B16-F10 cells cultured under normoxia (21% pO2, N) or hypoxia (0.1% pO2, H) conditions for 24 h. Bars are mean ± SEM from three independent experiments. ns = not significant, *** = p < 0.001 determined by unpaired two tailed Student’s t test. F Immunohistochemical staining of CCL5 (red) performed on HIF-1α (FL)and HIF-1α (Del) B16-F10 tumors. Scale bars: 200 μm.
Fig. 3 The infiltration of NK and CD8+ T cells into HIF-1α Del tumors is associated with the release of CCL5 from tumor cells. A Tumor growth curves of HIF-1α (FL) and HIF-1α (Del) B16-F10 cells transplanted in C57BL/6 mice untreated (Isotype) or treated with NK-depleting antibody (anti-NK1.1). Mice were injected intraperitoneally with 200 µg of Isotype or anti-NK1.1 three days before the engraftment tumor cells and at days 0, 4, 8, 11, 15, 18 and 22 after the engraftment. Results are reported as average of 10 mice per group for [HIF-1α (FL) + Isotype] and [HIF-1α (Del) + anti-NK] groups, and 8 mice per group for [HIF-1α (Del) + Isotype] group. Error bars represent mean ± SEM. ns = not significant, * = p < 0.05, ** = p < 0.01 and *** = p < 0.001 determined by unpaired two tailed Student’s t test. B Tumor growth curves of HIF-1α (FL) and HIF-1α (Del) B16-F10 cells transplanted in untreated (Isotype) or CD8a-depleted (anti-CD8a) C57BL/6 mice. Mice were injected intraperitoneally with 200 µg of Isotype or anti-CD8a antibody three days before the engraftment tumor cells and at days 0, 4, 8, 11, 15, 18 and 22 after the engraftment. Data are reported as average of 8 mice per group for [HIF-1α (FL) + Isotype] group, 5 mice per group for [HIF-1α (Del)+ Isotype] and 7 mice per group for [HIF-1α (Del)+ anti-CD8]. Error bars represent mean ± SEM. ns = not significant, ** = p < 0.01 and *** = p < 0.001 determined by unpaired one tailed Student’s t test. C Cytokines/chemokines profiling in tumor lysate of HIF-1α (FL) and HIF-1α (Del)B16-F10 tumors using Mouse XL Cytokine Array. Left panel: Cytokines/chemokines up- and down-regulated in HIF-1α (Del) compared to HIF-1α (FL) B16-F10 tumor are highlighted in red and in green, respectively. Right panel: signal ratio of HIF-1α Del/HIF-1α FL (Del/FL). Mouse XL Cytokine Array for cytokines/chemokines profiling was performed once. D ELISA quantification of CCL2 and CCL5 in tumor plasma of HIF-1α (FL)and HIF-1α (Del)B16-F10 tumors. Data are reported in pg/ml/g of tumor. Bars represent an average of 8 mice. Error bars represent mean ± SEM. ** = p < 0.01 determined by unpaired two tailed Student’s t test. E ELISA quantification of CCL2 and CCL5 released in the supernatant of HIF-1α (FL) and HIF-1α (Del) B16-F10 cells cultured under normoxia (21% pO2, N) or hypoxia (0.1% pO2, H) conditions for 24 h. Bars are mean ± SEM from three independent experiments. ns = not significant, *** = p < 0.001 determined by unpaired two tailed Student’s t test. F Immunohistochemical staining of CCL5 (red) performed on HIF-1α (FL)and HIF-1α (Del) B16-F10 tumors. Scale bars: 200 μm.CC BY · PubMed Central
Fig. 4 Pharmacological targeting of HIF-1α transcription activity using Acriflavine improves the therapeutic benefit of anti-PD-1 immune checkpoint- and TRP-2 vaccine-based cancer immunotherapy. A Quantification of the infiltration of CD45+ cells and lymphoid cells (NK, CD3+, CD4+, CD4+ eff, CD8, and Treg) and CD8/Treg ratio in control and ACF-treated B16-F10 tumors. Data are reported as the percentage (%) of CD45 and represent the mean ± SEM (error bars) of 5 tumors per group (each dot represents one tumor). Statistically significant differences (indicated by asterisks) are calculated compared to control tumors using an unpaired two-tailed Student’s t test (ns = not significant; * = p < 0.05; ** = p < 0.01). B ELISA quantification of CCL2 and CCL5 in tumor plasma of control and ACF-treated tumors. Data are reported in pg/ml/g of tumor and represent the mean ± SEM (error bars) of 5 tumors (each dot represents one tumor). Statistically significant differences (indicated by asterisks) are calculated compared to control tumors using an unpaired two-tailed Student’s t test (* = p < 0.05). C Schematic representation of the triple combination strategy including anti-PD-1, ACF, and TRP-2180-188 peptide in B16-F10 tumor-bearing mice. 0.2 × 106 B16-F10 cells were subcutaneously (s.c.) injected into the right flank of syngeneic host C57BL/6 mice at day 0. When tumors were palpable (typically at day 8), TRP-2180-188 peptide was injected s.c. (100 μg TRP-2180-188 and 50 μg CpG ODN emulsified in 100 μL of IFA) in the left posterior part of mice. The vaccination was boosted twice at day 12 and day 16 (blue arrows). Mice were injected intraperitoneally with 100 µg of anti-PD-1 or control isotype at days 10, 14, and 18 (green arrows). Daily ACF treatment (2 mg/kg) was administered intraperitoneally from day 12 to 19 (red arrows). D B16-F10 tumor growth curves and tumor weight of mice treated with either isotype (control), combined with anti-PD-1, TRP-2180-188, or ACF. Upper panels: B16-F10 tumor growth curves in mice treated with mono, double or triple combination of anti-PD-1, TRP-2180-188, and ACF. Lower panels: B16-F10 tumor weight (grams, g) at day 19. Results are reported as the average of 5 mice per group and shown as mean ± SEM (error bars). Absence of asterisks indicates no significant difference, * = p < 0.05, ** = p < 0.01, and *** = p < 0.001 determined by unpaired two-tailed Student’s t test. E Left panel: Kaplan–Meier median survival curves of the two melanoma patient cohorts expressing high and low CCL5 mRNA. Patients displaying high CCL5 have significantly improved median survival compared to those having low CCL5. A p value of 0.0001 was determined using the Log-rank (Mantel-Cox) test. Right panel: Winter hypoxia score of patients expressing low and high CCL5 mRNA. F-I The expression of markers for different immune cells in melanoma patient cohorts described in (E). (F) NCR1 and NCR3 for NK cells; (G) CD3D and CD3E for CD3 cells; (H) CD4 for CD4; and (I) CD8A and CD8B for CD8 T cells. Statistically significant differences (indicated by asterisks) are calculated compared to patients expressing low CCL5 mRNA using an unpaired two-tailed Student’s t test (****** = p < 0.0001).
Fig. 4 Pharmacological targeting of HIF-1α transcription activity using Acriflavine improves the therapeutic benefit of anti-PD-1 immune checkpoint- and TRP-2 vaccine-based cancer immunotherapy. A Quantification of the infiltration of CD45+ cells and lymphoid cells (NK, CD3+, CD4+, CD4+ eff, CD8, and Treg) and CD8/Treg ratio in control and ACF-treated B16-F10 tumors. Data are reported as the percentage (%) of CD45 and represent the mean ± SEM (error bars) of 5 tumors per group (each dot represents one tumor). Statistically significant differences (indicated by asterisks) are calculated compared to control tumors using an unpaired two-tailed Student’s t test (ns = not significant; * = p < 0.05; ** = p < 0.01). B ELISA quantification of CCL2 and CCL5 in tumor plasma of control and ACF-treated tumors. Data are reported in pg/ml/g of tumor and represent the mean ± SEM (error bars) of 5 tumors (each dot represents one tumor). Statistically significant differences (indicated by asterisks) are calculated compared to control tumors using an unpaired two-tailed Student’s t test (* = p < 0.05). C Schematic representation of the triple combination strategy including anti-PD-1, ACF, and TRP-2180-188 peptide in B16-F10 tumor-bearing mice. 0.2 × 106 B16-F10 cells were subcutaneously (s.c.) injected into the right flank of syngeneic host C57BL/6 mice at day 0. When tumors were palpable (typically at day 8), TRP-2180-188 peptide was injected s.c. (100 μg TRP-2180-188 and 50 μg CpG ODN emulsified in 100 μL of IFA) in the left posterior part of mice. The vaccination was boosted twice at day 12 and day 16 (blue arrows). Mice were injected intraperitoneally with 100 µg of anti-PD-1 or control isotype at days 10, 14, and 18 (green arrows). Daily ACF treatment (2 mg/kg) was administered intraperitoneally from day 12 to 19 (red arrows). D B16-F10 tumor growth curves and tumor weight of mice treated with either isotype (control), combined with anti-PD-1, TRP-2180-188, or ACF. Upper panels: B16-F10 tumor growth curves in mice treated with mono, double or triple combination of anti-PD-1, TRP-2180-188, and ACF. Lower panels: B16-F10 tumor weight (grams, g) at day 19. Results are reported as the average of 5 mice per group and shown as mean ± SEM (error bars). Absence of asterisks indicates no significant difference, * = p < 0.05, ** = p < 0.01, and *** = p < 0.001 determined by unpaired two-tailed Student’s t test. E Left panel: Kaplan–Meier median survival curves of the two melanoma patient cohorts expressing high and low CCL5 mRNA. Patients displaying high CCL5 have significantly improved median survival compared to those having low CCL5. A p value of 0.0001 was determined using the Log-rank (Mantel-Cox) test. Right panel: Winter hypoxia score of patients expressing low and high CCL5 mRNA. F-I The expression of markers for different immune cells in melanoma patient cohorts described in (E). (F) NCR1 and NCR3 for NK cells; (G) CD3D and CD3E for CD3 cells; (H) CD4 for CD4; and (I) CD8A and CD8B for CD8 T cells. Statistically significant differences (indicated by asterisks) are calculated compared to patients expressing low CCL5 mRNA using an unpaired two-tailed Student’s t test (****** = p < 0.0001).CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

1 more claim about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 30 references

Cited by

See all 136

Metadata

Authors
Lequeux, A., Noman, M. Z., Xiao, M., Van Moer, K., Hasmim, M., Benoit, A., Bosseler, M., Viry, E., Arakelian, T., Berchem, G., Chouaib, S., & Janji, B.
Affiliations
  • Luxembourg Institute of Health (LU)
  • Centre Hospitalier de Luxembourg (LU)
Corresponding author
Janji, Bassam
Venue
Oncogene
Published
2021-06-21
Volume
40
Issue
28
Pages
4725-4735
ISSN
  • 0950-9232 (ISSN-L)
  • 1476-5594
OpenAlex
W3176619285
Cited by
129
References
30
Citations by year
2026: 9 · 2025: 25 · 2024: 28 · 2023: 25 · 2022: 34 · 2021: 8
FWCI
9.28
Type
journal article
Language
en
Open access
Licence
Locations
  • Oncogene (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
  • Fondation Cancer (FC/2018/06)
  • Fonds National de la Recherche Luxembourg (PRIDE15/10675146/ CANBIO, 10675146, PRIDE 15/10675146/)
  • Fonds De La Recherche Scientifique - FNRS (PRIDE15/10675146/CANBIO, 7.4606.18)
  • Action LIONS Vaincre le Cancer
  • Cilag
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords
HIF-1α, hypoxia, melanoma, tumor immune microenvironment, natural killer cells, CD8+ T cells, RANTES, MCP-1, acriflavine, anti-PD-1 therapy, combination immunotherapy, tumor hypoxia, patient survival
MeSH terms
Animals, Humans, Immunotherapy, Killer Cells, Natural, Melanoma, Melanoma, Experimental, Mice, Inbred C57BL, CD8-Positive T-Lymphocytes, Chemokine CCL5, Cell Line, Tumor, Mice, Hypoxia-Inducible Factor 1, alpha Subunit, Tumor Microenvironment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Targeting HIF-1 alpha transcriptional activity drives cytotoxic immune effector cells into melanoma and improves combination immunotherapy. https://app.cochat.ai/papers/10.1038/s41388-021-01846-x
The paper
Lequeux, A., Noman, M. Z., Xiao, M., Van Moer, K., Hasmim, M., Benoit, A., Bosseler, M., Viry, E., Arakelian, T., Berchem, G., Chouaib, S., & Janji, B. (2021). Targeting HIF-1 alpha transcriptional activity drives cytotoxic immune effector cells into melanoma and improves combination immunotherapy. Oncogene. https://doi.org/10.1038/s41388-021-01846-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.